Purpose: To build a physiologically based pharmacokinetic (PBPK) model for fimasartan, amlodipine, and hydrochlorothiazide, and to investigate the drug-drug interaction (DDI) potentials.
Methods: The PBPK model of each drug was developed using Simcyp software (Version 15.0), based on the information obtained from literature sources and in vitro studies. The predictive performance of the model was assessed by comparing the predicted PK profiles and parameters with the observed data collected from healthy subjects after multiple oral doses of fimasartan, amlodipine, and hydrochlorothiazide. The DDI potentials after co-administration of three drugs were simulated using the final model.
Results: The predicted-to-observed ratios of all the pharmacokinetic parameters met the acceptance criterion. The PBPK model predicted no significant DDI when fimasartan was co-administered with amlodipine or hydrochlorothiazide, which is consistent with the observed clinical data. In the simulation of DDI at steady-state after co-administration of three drugs, the model predicted that fimasartan exposure would be increased by ~24.5%, while no changes were expected for the exposures of amlodipine and hydrochlorothiazide.
Conclusions: The developed PBPK model adequately predicted the pharmacokinetics of fimasartan, amlodipine, and hydrochlorothiazide, suggesting that the model can be used to further investigate the DDI potential of each drug.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11095-018-2511-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spectrophotometric method based on Continuous wavelet transform and ratio substraction methods for the rapid simultaneous quantification of Valsartan, Amlodipine, and hydrochlorothiazide in cardiovascular tablet formulation.
Spectrochim Acta A Mol Biomol Spectrosc
January 2025
Department of Chemistry, North Tehran Branch, Islamic Azad University, Tehran, Iran. Electronic address:
The present study quantified simultaneous determination of the active components included in Valzomix HCT tablets are hydrochlorothiazide (HCT), valsartan (VAL), and amlodipine (AML). Two chemometric methods-continuous wavelet transform (CWT) and ratio subtraction (RS)-along with a rapid and effective spectrophotometric approach-which does not require preparatory separation-were used to do the analysis. The CWT approach applied the zero-crossing method to analyze several wavelet families and selected the Daubechies 2, Symlet 2, and Biorthogonal 1.
View Article and Find Full Text PDFAngiotensin-Converting Enzyme Inhibitor (ACEI) and Angiotensin Receptor Blocker (ARB) Use are Associated With Increased Readmission After Ileostomy Creation.
Am Surg
December 2024
Kaiser Permanente Northwest, Portland, OR, USA.
Background: High output is a common cause for readmission after new ileostomy creation. The loss of sodium leads to compensatory activation of the renin-angiotensin-aldosterone system (RAAS). Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are first-line therapy for hypertension in the United States.
View Article and Find Full Text PDFRetraction notice to "Simultaneous determination of hydrochlorothiazide, amlodipine, and telmisartan with spectrophotometric and HPLC green chemistry applications"[Chemosphere 303 (2022) 135074].
Chemosphere
February 2025
Department of Chemistry, Soongsil University, Seoul, 06978, South Korea; Department of Sustainable Engineering, Saveetha School of Engineering, SIMATS, Chennai, 602105, India; Department of Chemical Engineering, Quchan University of Technology, Quchan, Iran.
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/policies/article-withdrawal).
View Article and Find Full Text PDFPharmacogenomics assists in controlling blood pressure in cardiovascular and cerebrovascular patients during Rehabilitation: a case report.
Front Pharmacol
October 2024
Department of Rehabilitation, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China.
Hypertension is a common risk factor for cardiovascular disease. Pharmacogenomics, as a tool for personalized healthcare, helps in determining the optimal drug treatment based on the genome of individual patient. This study reports a 49-year-old male with acute cerebral infarction, pulmonary infection, extremely high-risk hypertension (grade3), type 2 diabetes, hyperhomocysteinemia, hyperlipidemia, and fatty liver.
View Article and Find Full Text PDFDrug-induced hyponatraemia and possible related signals: Analysis of 659 cases reported to the Spanish Pharmacovigilance System and disproportionality analysis.
Med Clin (Barc)
December 2024
Centre for Research on Drug Safety (CESME), Department of Cell Biology, Histology, Pharmacology and Genetics, Faculty of Medicine, University of Valladolid (Centro de Estudios Sobre la Seguridad de los Medicamentos (CESME), Departamento de Biología Celular, Histología, Farmacología y Genética, Facultad de Medicina, Universidad de Valladolid), Valladolid, Spain; Research Group Pharmacogenetics, Cancer Genetics, Genetic Polymorphisms and Pharmacoepidemiology, University of Valladolid (GIR Farmacogenética, Genética del Cáncer, Polimorfismos Genéticos y Farmacoepidemiología, Universidad de Valladolid), Spain. Electronic address:
Article Synopsis
- Hyponatraemia can adversely affect cognitive function and increase risks for falls, fractures, and even hospital mortality.
- The objective of the study was to identify safety signals related to drug-induced hyponatraemia and analyze cases reported in the Spanish Pharmacovigilance System.
- The analysis revealed 659 cases of suspected drug-induced hyponatraemia, with a significant increase over five years; most cases were serious, affecting primarily elderly women, and were commonly associated with diuretics and antidepressants.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!